Literature DB >> 7494597

Microglial interleukin-1 alpha expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution.

J G Sheng1, R E Mrak, W S Griffin.   

Abstract

Interleukin-1 alpha-immunoreactive (IL-1 alpha+) microglia are prominent components of neuritic plaques in Alzheimer's disease, and may be important in the evolution of neuritic plaques from diffuse amyloid deposits. Neuritic plaques show a characteristic distribution across cerebral regions and are absent in the cerebellum of patients with Alzheimer's disease. We used single- and dual-immunohistochemical labelling to investigate the possibility that the expression of IL-1 alpha is correlated with this regional distribution of neuritic (tau 2-immunoreactive, tau 2+) plaques. In Alzheimer's disease, tau 2+ neuritic plaques occurred with increasing frequency in grey matter of frontal and occipital lobes, temporal lobe, and hippocampus. There were positive correlations between the regional patterns of distribution of activated IL-1 alpha+ microglia and tau 2+ neuritic plaques as well as between activated IL-1 alpha+ microglia and activated astrocytes. No activated IL-1 alpha+ microglia, tau 2+ neuritic plaques, or activated astrocytes were observed in cerebellum of these Alzheimer patients. These regional relationships between activated IL-1 alpha+ microglia, tau 2+ neuritic plaques, and activated astrocytes, together with the established functions of IL-1, support a causal association between the overexpression of IL-1 and the evolution of beta-amyloid deposits into neuritic plaques in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494597     DOI: 10.1111/j.1365-2990.1995.tb01063.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  37 in total

1.  Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease.

Authors:  L N Nilsson; K R Bales; G DiCarlo; M N Gordon; D Morgan; S M Paul; H Potter
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

Review 2.  The pervasiveness of interleukin-1 in alzheimer pathogenesis: a role for specific polymorphisms in disease risk.

Authors:  W S Griffin; J A Nicoll; L M Grimaldi; J G Sheng; R E Mrak
Journal:  Exp Gerontol       Date:  2000-07       Impact factor: 4.032

3.  Changes in APP, PS1 and other factors related to Alzheimer's disease pathophysiology after trimethyltin-induced brain lesion in the rat.

Authors:  Camilla Nilsberth; Beata Kostyszyn; Johan Luthman
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

4.  Neuroinflammatory Cytokines-The Common Thread in Alzheimer's Pathogenesis.

Authors:  W Sue T Griffin; Steven W Barger
Journal:  US Neurol       Date:  2010

Review 5.  Interleukin-1 and the immunogenetics of Alzheimer disease.

Authors:  R E Mrak; W S Griffin
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

Review 6.  Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?

Authors:  Stefan Prokop; Virginia M Y Lee; John Q Trojanowski
Journal:  Prog Mol Biol Transl Sci       Date:  2019-10-24       Impact factor: 3.622

Review 7.  Glial cell dysregulation: a new perspective on Alzheimer disease.

Authors:  Rommy von Bernhardi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

8.  Genetic polymorphism of interleukin 1β -511C/T and susceptibility to sporadic Alzheimer's disease: a meta-analysis.

Authors:  Hai Yuan; Qing Xia; Pingping Ge; Shaowei Wu
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

Review 9.  Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease.

Authors:  W Sue T Griffin; Robert E Mrak
Journal:  J Leukoc Biol       Date:  2002-08       Impact factor: 4.962

10.  S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta12,14- prostaglandin J2 (15d-PGJ2).

Authors:  Tammy Kielian; Meredith McMahon; Edward D Bearden; Aaron C Baldwin; Paul D Drew; Nilufer Esen
Journal:  J Neurochem       Date:  2004-09       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.